Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Aprea Therapeutics, Inc. (APRE)
|
Add to portfolio |
|
|
Price: |
$3.07
| | Metrics |
OS: |
3.74
|
M
| |
|
|
Market cap: |
$11.5
|
M
| |
|
|
Net cash:
|
$27.7
|
M
| |
$7.41
|
per share
|
EV:
|
|
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 |
Revenues | 0.0 | 0.0 | 0.0 |
Cost of goods sold | 0.0 | 0.0 | 0.0 |
Gross profit | 0.0 | 0.0 | 0.0 |
Research and development | 21.0 | 14.2 | 13.4 |
General and administrative | 8.6 | 2.3 | 2.5 |
EBIT | -28.4 | -15.5 | -15.2 |
Pre-tax income | -28.1 | -15.5 | -15.2 |
Income taxes | 0.0 | 0.0 | 0.0 |
Tax rate | 0.0% | 0.0% | 0.0% |
Net income | -28.1 | -15.5 | -15.2 |
|
Diluted EPS | ($4.67) | ($13.45) | ($13.17) |
Shares outstanding (diluted) | 6.0 | 1.2 | 1.2 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|